Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of...

Full description

Saved in:
Bibliographic Details
Published in:CA: a cancer journal for clinicians Vol. 62; no. 6; pp. 394 - 399
Main Authors: Maluccio, Mary, Covey, Anne
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.11.2012
Wiley Subscription Services, Inc
Subjects:
Ablation Techniques
Algorithms
Benzenesulfonates - therapeutic use
Cancer
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - therapy
Chemoembolization, Therapeutic
decision‐making/patient preferences
Embolization, Therapeutic - methods
Humans
liver neoplasms
Liver Neoplasms - diagnosis
Liver Neoplasms - therapy
Liver Transplantation
Medical diagnosis
Medical treatment
Niacinamide - analogs & derivatives
Phenylurea Compounds
Protein Kinase Inhibitors - therapeutic use
Pyridines - therapeutic use
Radiosurgery
ISSN:0007-9235, 1542-4863, 1542-4863
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient‐related variables such as comorbid conditions that influence treatment eligibility; 2) liver‐related variables such as Child‐Pugh score; and 3) tumor‐related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. CA Cancer J Clin 2012;. © 2012 American Cancer Society.
Bibliography:The authors report no conflicts of interest.
DISCLOSURES
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0007-9235
1542-4863
1542-4863
DOI:10.3322/caac.21161